ArticleCancer medicine2025
Tertiary Lymphoid Structures as Independent Predictors of Favorable Prognosis in Muscle-Invasive Bladder Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Article
- From mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer.World journal of surgical oncology · 2026Review
- Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.Frontiers in immunology · 2026Observational
- Germinal Center-Like Tertiary Lymphoid Structures Mark Immune Responsiveness and Enable Checkpoint Immunotherapy in Bladder Cancer.Oncology research · 2026Article
- Case Report: Mature tertiary lymphoid structures in a metastatic urothelial carcinoma patient with an exceptional response to sequential immune checkpoint inhibitor and antibody-drug conjugate therapy.Frontiers in oncology · 2026Article
- Unraveling the dual roles of tumor-infiltrating antibodies in solid tumors: friend or foe in the tumor microenvironment?Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTertiary lymphoid structure (TLS) has been reported to be associated with prognosis and immunotherapy in certain cancers. The objective of our study was to investigate the prognostic significance of Tertiary Lymphoid Structures (TLS) within the context of Muscle-Invasive Bladder Cancer (MIBC), while concurrently examining the clinicopathological and molecular determinants influencing TLS formation.
methodsImmunohistochemistry was used to detect the expression of TLS, CD8+ T cells, B cells, and plasma cells in 119 MIBC cases, of which 80 cases were tested by next generation sequencing (NGS) for analyzing the differences in gene alterations between TLS-negative and TLS-positive.
resultsTLS were identified in 52.1% (62/119) of the MIBC cases studied. Patients exhibiting TLS demonstrated reduced T and TNM staging and prolonged overall survival (OS) compared to those lacking TLS. Multivariate analysis showed that TLS was an independent prognostic factor. Densities of B cells, CD8+ T cells, and plasma cells in tumors were significantly correlated with TLS, but in the cases with low-density B cells, high-density CD8+ T cells, or high-density plasma cells, differences in OS between the tumors with TLS and without TLS were not significant. Compared with TLS-negative tumors, TLS-positive tumors had a lower frequency of TP53 mutations and higher frequencies of FAT1 and CDKN1A mutations. Tumor mutational burden (TMB) was not significantly different between the two groups but was significantly associated with TLS in TP53 wild-type tumors.
conclusionsTLS emerged as an independent harbinger of favorable prognosis in MIBC, predominantly mediating antitumor responses via B cells. Moreover, TP53 mutations were identified as a potential inhibitor of TLS formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.